insights_auto
Why is DMN down 5.11%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€0.059
arrow_downward
-5.11%(-0.0032) 1D
Nov 20, 10:00:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
135.12M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
135.12M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
The Motley Fool
·
8 minutes ago
In the Last Tech Bust, the S&P 500 Lost Money for a Decade. History Says Stocks With the Highest Yields Gained 5.4% a Year.
Benzinga
·
39 minutes ago
Four S&P 500 Stocks Rising in a Falling Market: Pentair, AppLovin, Chipotle, and Gen Digital
Nacionale
·
2 hours ago
Is the S&P 500 in a bear market, and will it rally? No, it's in a correction, 11.6% below its record
Yahoo Finance
·
3 hours ago
T-Bills Are Beating the Nasdaq, S&P 500 and Dow This Year
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitediamyd.com